Sio Gene Therapies

Last updated
Sio Gene Therapies, Inc.
FormerlyAxovant Gene Therapies
Company type Public
Nasdaq: SIOX
Industry Biopharmaceutical
FoundedOctober 2014;9 years ago (2014-10)
Founder Vivek Ramaswamy
DefunctApril 5, 2023 (2023-04-05)
Headquarters New York City
Key people
Pavan Cheruvu (CEO)
Owner Roivant Sciences (25%)
Website siogtx.com

Sio Gene Therapies, Inc. (formerly known as Axovant Gene Therapies) was a clinical-stage pharmaceutical company that developed gene therapies to treat neurological disorders. The company was headquartered in New York City and was incorporated in Basel, Switzerland. The company was founded by former hedge fund analyst and 2024 Republican Party presidential primary candidate Vivek Ramaswamy [1] in October 2014 as a wholly owned subsidiary of Roivant Sciences, which was itself founded in May 2014. [2]

History

In December 2014, Axovant acquired rights to the drug intepirdine from GlaxoSmithKline. [3] Intepirdine is a potential add-on treatment to donepezil for patients with Alzheimer's disease and patients with dementia with Lewy bodies. [4] [1] [5] GlaxoSmithKline had sold the rights to Axovant for only $5 million, a very small amount in the pharmaceutical industry, because four clinical trials had resulted in failure. [6] [7] Intepirdine was Axovant's only product. [8]

Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]

In July 2017, Axovant announced that the results of a phase III trial indicated that the drug was not effective for treatment of Alzheimer's disease. [12] [13] Axovant's stock lost 75 percent of its value in a single day. [14] It has been accused of being a pump-and-dump scheme. [15] [16] [17] [18]

The company also entered clinical trials for dementia with Lewy bodies, [19] which were unsuccessful as well. Consequently, Axovant announced in 2018 that it has discontinued development of intepirdine. [20]

As of 2016 Axovant was also developing a second compound, nelotanserin. Axovant acquired global rights to nelotanserin from its former parent, Roivant, which had previously bought those rights from Arena Pharmaceuticals [5] and intended to develop it as a treatment for Lewy body dementia. [21] However, in late 2018, the company announced that nelotanserin failed to meet its primary endpoint of reducing the frequency of REM sleep behavior disorder (RBD) episodes in a small Phase 2 clinical trial for the treatment of RBD in LBD patients, the drug and would be discontinued. [22]

In 2016 Axovant partnered with NFL broadcaster Solomon Wilcots to raise awareness of Alzheimer's clinical trials [23] [24] That year it also sponsored performances in several U.S cities of “Forget Me Not,” a play by Garrett Davis about an African American family coping with Alzheimer’s disease, [23] in order to raise awareness of its clinical trials in that community, because African Americans are twice as likely to develop Alzheimer’s disease as white Americans, but have been historically underrepresented in clinical research studies. [25]

Axovant logo from 2014 to 2020 Axovant Gene Therapies Corporate Logo.svg
Axovant logo from 2014 to 2020

Also in 2016, Axovant partnered with the mobile rideshare service Lyft to transport patients in Alzheimer's disease studies to clinical facilities. [26]

In 2017, David Hung joined the company as CEO. [27]

In 2018, David Hung resigned and Pavan Cheruvu became the new CEO. [28]

In December 2018, Axovant added two gene therapy programs[ which? ] to treat GM1 gangliosidosis and Tay–Sachs and Sandhoff diseases. [29] [30]

In June 2019, Axovant announced a strategic partnership with Yposkesi, a leading Contract Development and Manufacturing Organization, to expand Axovant's gene therapy manufacturing capacity. [31]

In August 2019, Axovant was preparing to report data from all three clinical-stage programs in the fourth quarter of 2019, including results from the second cohort of the AXO-LENTI-PD study and data from additional children dosed with AXO-AAV-GM1 and AXO-AAV-GM2.

In November 2020, Axovant rebranded as Sio Gene Therapies. [32]

On April 5, 2023, the shareholders of Sio Gene Therapies voted to liquidate and dissolve the company. [33]

Related Research Articles

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen operates in Argentina, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Sweden, and Switzerland.

<span class="mw-page-title-main">Donepezil</span> Medication used for dementia

Donepezil, sold under the brand name Aricept among others, is a medication used to treat dementia of the Alzheimer's type. It appears to result in a small benefit in mental function and ability to function. Use, however, has not been shown to change the progression of the disease. Treatment should be stopped if no benefit is seen. It is taken by mouth or via a transdermal patch.

Takeda Oncology is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.

TauRx Therapeutics Ltd is a life sciences/pharmaceutical company incorporated in Singapore with primary research facilities and operations in Aberdeen, Scotland.

<span class="mw-page-title-main">Pimavanserin</span> Atypical antipsychotic medication

Pimavanserin, sold under the brand name Nuplazid, is an atypical antipsychotic which is approved for the treatment of Parkinson's disease psychosis and is also being studied for the treatment of Alzheimer's disease psychosis, schizophrenia, agitation, and major depressive disorder. Unlike other antipsychotics, pimavanserin is not a dopamine receptor antagonist.

<span class="mw-page-title-main">Intepirdine</span> Chemical compound

Intepirdine (INN; developmental codes SB-742457, RVT-101) is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects. It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials. GSK chose not to continue development and sold the rights to Axovant Sciences for $5 million in December 2014.

<span class="mw-page-title-main">Nelotanserin</span> Chemical compound

Nelotanserin is a drug developed by Arena Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A and was under development for the treatment of insomnia. It was shown to be effective and well tolerated in clinical trials, but development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints. Research continues on newer analogues which may potentially be more successful.

<span class="mw-page-title-main">Rivastigmine</span> Chemical compound

Rivastigmine is a cholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Sorrento Valley, San Diego, California.

Crenezumab is a fully humanized monoclonal antibody against human 1-40 and 1-42 beta amyloid, which is being investigated as a treatment of Alzheimer's disease. Crenezumab is highly homologous to solanezumab, another monoclonal antibody targeting amyloid-β peptides. In June 2022, the US National Institutes of Health announced that the drug failed as a medication for early-onset Alzheimer's disease following the results of a decade-long clinical trial.

<span class="mw-page-title-main">Brexpiprazole</span> Atypical antipsychotic

Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease.

Flexion Therapeutics, Inc. is an American biopharmaceutical company based in Burlington, Massachusetts that is focused on the discovery, development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), the most common form of arthritis.

<span class="mw-page-title-main">Kadmon Corporation</span> Biopharmeceutical company based in New York City

Kadmon Corporation is a biopharmaceutical company based in New York City. It also has operations in Warrendale, PA and Brighton, MA. The company was founded in 2009 by Samuel D. Waksal, founder and former CEO of ImClone Systems, now fully merged into Eli Lilly and Company. Waksal had served a federal prison sentence stemming from his fiduciary role as CEO in the 2001 ImClone stock trading case. When released in 2009 he was barred from serving as an officer for any publicly traded company but Kadmon was privately financed.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

Adverum Biotechnologies, Inc., formerly known as Avalanche Biotechnologies, is a publicly traded clinical stage gene therapy company located in Redwood City, California. The company is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration.

Roivant Sciences Ltd. is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies. It was founded in 2014 by Vivek Ramaswamy.

<span class="mw-page-title-main">Vivek Ramaswamy</span> American businessman (born 1985)

Vivek Ganapathy Ramaswamy is an American entrepreneur. He founded Roivant Sciences, a pharmaceutical company, in 2014. In February 2023, Ramaswamy declared his candidacy for the Republican Party nomination in the 2024 United States presidential election. He suspended his campaign in January 2024, after finishing fourth in the Iowa caucuses.

<span class="mw-page-title-main">Alzheon</span>

Alzheon is an American clinical-stage biopharmaceutical company based in Framingham, Massachusetts. The company is developing medicines for patients with Alzheimer's disease and other neurological and psychiatric disorders.

<span class="mw-page-title-main">ProQR</span> Dutch biotechnology company

ProQR Therapeutics NV is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. The company was funded in 2012 by chief executive officer (CEO) Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer.

<span class="mw-page-title-main">CRISPR Therapeutics</span> Swiss-American biotechnology company

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.

References

  1. 1 2 Karerat, Raif (12 Jun 2015). "Axovant Sciences founded by Indian American Vivek Ramaswamy has biggest US biotech IPO". The American Bazaar. Germantown, Maryland: Global Media Holding.
  2. ↑ "10-K For the fiscal year ended March 31, 2016". Axovant via SEC Edgar. June 6, 2016.
  3. ↑ Pollack, Andrew (11 Jun 2015). "Shares of Axovant, Alzheimer's Drug Developer, Surge on Trading Debut". New York Times .
  4. 1 2 Staff (12 Jun 2015). "Axovant doubles in value after $315M IPO". Pharmaceutical Processing . Associated Press.
  5. 1 2 Crow, David (2015-11-02). "Axovant prepares to start pair of dementia drugs trials". Financial Times. ISSN   0307-1766 . Retrieved 2016-01-07.
  6. ↑ "Axovant Abandons Another Dementia Drug After Failed Trial". BioSpace. Retrieved 2023-09-14.
  7. ↑ Weisman, Jonathan; Robbins, Rebecca; Farrell, Maureen (2023-06-27). "How Vivek Ramaswamy Made the Fortune Fueling His Presidential Run". The New York Times. ISSN   0362-4331 . Retrieved 2023-09-14.
  8. ↑ https://www.fiercebiotech.com/biotech/why-axovant-s-315m-ipo-bonanza-should-scare-hell-out-of-you
  9. ↑ Stevenson, Abigail (2015-06-11). "Biggest biotech IPO ever—and the CEO is 29!". CNBC. Retrieved 2023-09-14.
  10. ↑ https://www.sec.gov/Archives/edgar/data/1636050/000163605016000042/a3311610k.htm
  11. ↑ Feuerstein, Adam (2015-06-08). "Inside the Hedge Fund Club Pitching a New Alzheimer's Drug IPO". TheStreet. Retrieved 2023-09-14.
  12. ↑ Garde, Damian (26 September 2017). "Another Alzheimer's failure: Axovant's drug flops in late-stage trial". STAT.
  13. ↑ Herper, Matthew (September 26, 2017). "Axovant Alzheimer's Drug Fails To Help Patients". Forbes.
  14. ↑ Weisman, Jonathan; Robbins, Rebecca; Farrell, Maureen (2023-06-27). "How Vivek Ramaswamy Made the Fortune Fueling His Presidential Run". The New York Times. ISSN   0362-4331 . Retrieved 2023-09-14.
  15. ↑ "Smoke and mirrors: I've been debating Vivek Ramaswamy for 2 years. Here's how I got past his diversionary tactics". Fortune. Retrieved 2023-09-14.
  16. ↑ "Vivek Ramaswamy is threatening GOP heavyweights in the polls–but his business record doesn't live up to the hype". Fortune. Retrieved 2023-09-14.
  17. ↑ Piper, Jessica (2023-05-14). "How Vivek Ramaswamy made a fortune before pivoting to politics". POLITICO. Retrieved 2023-09-14.
  18. ↑ Weisman, Jonathan; Robbins, Rebecca; Farrell, Maureen (2023-06-27). "How Vivek Ramaswamy Made the Fortune Fueling His Presidential Run". The New York Times. ISSN   0362-4331 . Retrieved 2023-09-14.
  19. ↑ "Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2023-09-14.
  20. ↑ "Axovant slumps as it dumps lead drug intepirdine". Fierce Biotech. Jan 8, 2018.
  21. ↑ Grover, Natalie (28 Apr 2016). "Acadia drug approval could clear way for Axovant dementia therapy". Reuters.
  22. ↑ "Axovant Reports Results of Exploratory Phase 2 Clinical Study of Nelotanserin in Lewy Body Dementia Patients Experiencing REM Sleep Behavior Disorder". Sio Gene Therapies. December 10, 2018. Retrieved 7 May 2023.
  23. 1 2 Henriques, Carolina (26 January 2016). "'Huddle Up for Alzheimer's' Campaign Encourages Clinical Trial Participation". Alzheimer's News Today. Retrieved 14 November 2016.
  24. ↑ Leuty, Ron (9 February 2016). "On sports' biggest stage, drug developers tap athletes' connections". San Francisco Business Times. Retrieved 14 November 2016.
  25. ↑ Kunkle, Frederick (23 November 2014). "Alzheimer's risk is higher in African Americans, but many fear clinical studies". The Washington Post. Retrieved 14 November 2016.
  26. ↑ Rockoff, Jonathan (18 July 2016). "Companies Try New Ways to Attract Patients to Drug Trials". The Wall Street Journal. Retrieved 14 November 2016.
  27. ↑ Taylor, Nick Paul (April 10, 2017). "Axovant stock jumps as Medivation founder takes CEO post". FierceBiotech.
  28. ↑ "Axovant Sciences Announces Changes to Management Team and Board of Directors | Axovant Sciences, Inc". Axovant Sciences, Inc. Retrieved 2018-02-12.
  29. ↑ Keown, Alex (14 December 2018). "Axovant Licenses Two Gene Therapies Aimed at Tay–Sachs and Sandhoff Disease". BioSpace (Press release).
  30. ↑ Taylor, Nick Paul (14 December 2018). "Axovant buys more gene therapies, setting it up for a busy 2019". FierceBiotech (Press release).
  31. ↑ "Yposkesi enters into strategic partnership to expand Axovant's gene therapy manufacturing capacity" . Retrieved 2020-03-18.
  32. ↑ Gelman, Max. "'We're not a vant': Axovant seeks to forget the past as the company rebrands to Sio Gene Therapies". Endpoints News.
  33. ↑ "Sio Gene Therapy".
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.